2008

Lichtenberg, Frank R and Duflos, Gautier (2008) Pharmaceutical Innovation and the Longevity of Australians : A First Look. In: Beyond Health Insurance : Public Policy to Improve Health. Helmchen, Lorens, Kaestner, Robert and Lo Sasso, Anthony, eds. Emerald Publishing Group, Bingley, W. Yorks, UK, pp. 95-117.

2009

Lichtenberg, Frank R (2009) International differences in cancer survival rates: the role of new drug launches. International Journal of Healthcare Technology and Management, 10 (3). pp. 138-155. ISSN 1368-2156

Lichtenberg, Frank R and Waldfogel, Joel (2009) Does Misery Love Company? Evidence from Pharmaceutical Markets Before and After the Orphan Drug Act. Michigan Telecommunications and Technology Law Review, 15 (2). pp. 335-357. ISSN 1528-8625

Lichtenberg, Frank R (2009) Home, or nursing home? The effect of medical innovation on the demand for long-term care. In: The Economics of New Health Technologies: Incentives, Organisation and Financing. Costa-Font, Joan, Courbage, Christophe and McGuire, Alistair, eds. Oxford University Press, Oxford, UK, pp. 241-258.

May 2009

Lichtenberg, Frank R (2009) Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Economics, 18 (5). pp. 519-534. ISSN 1057-9230

July 2009

Lichtenberg, Frank R (2009) The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978–2004. Economics of Innovation and New Technology, 18 (5). pp. 407-428. ISSN 1043-8599 (print), 1476-8364 (online)

September 2009

Lichtenberg, Frank R, Grootendorst, Paul, Van Audenrode, Marc, Latremouille-Viau, Dominick and Lefebvre, Patrick (2009) The Impact of Drug Vintage on Patient Survival: A Patient-Level Analysis Using Quebec’s Provincial Health Plan Data. Value in Health, 12 (6). pp. 847-856. ISSN 1098-3015

December 2009

Lichtenberg, Frank R (2009) Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Review of Pharmacoeconomics and Outcomes Research , 9 (6). pp. 499-504. ISSN 1473-7167

2010

Lichtenberg, Frank R (2010) The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program. Advances in Health Economics and Health Services Research, 22. pp. 273-292. ISSN 0731-2199

April 2010

Lichtenberg, Frank R (2010) Pharmaceutical innovation and mortality in the United States, 1960–2000. A commentary on Schnittker and Karandinos. Social Science & Medicine, 70 (7). pp. 969-971. ISSN 0277-9536

July 2010

Lichtenberg, Frank R (2010) Pharmaceutical Price Discrimination and Social Welfare. Capitalism and Society, 5 (1). pp. 1-29. ISSN 1932-0213

August 2010

Lichtenberg, Frank R (2010) Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Re-examination Using Data From the U.S. and Australia. Forum for Health Economics & Policy, 13 (2). pp. 1-17. ISSN 1558-9544 (online)

February 2011

Sampat, Bhaven N and Lichtenberg, Frank R (2011) What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation? Health Affairs, 30 (2). pp. 332-339. ISSN 0278-2715

March 2011

Lichtenberg, Frank R (2011) The Quality of Medical Care, Behavioral Risk Factors and Longevity growth. International Journal of Health Care Finance and Economics, 11 (1). pp. 1-34. ISSN 1389-6563

Lichtenberg, Frank R (2011) Despite Steep Costs, Payments for New Cancer Drugs Make Economic Sense. Nature Medicine, 17 (3). p. 244. ISSN 1078-8956

July 2011

Lichtenberg, Frank R (2011) Has Pharmaceutical Innovation Reduced Social Security Disability Growth? International Journal of the Economics of Business, 18 (2). pp. 293-316. ISSN 1357-1516

2012

Lichtenberg, Frank R (2012) Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001-7. PharmacoEconomics, 30 (3). pp. 197-211. ISSN 1170-7690 (print) 1179-2027 (online)

March 2012

Duflos, Gautier and Lichtenberg, Frank R (2012) Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization. International Review of Law and Economics, 32 (1). pp. 95-109. ISSN 0144-8188

2013

Lichtenberg, Frank R (2013) The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007. European Journal of Health Economics, 14 (1). pp. 41-56. ISSN 1618-7598